[Rosiglitazone: a clinical development focused on cardio-vascular prevention].
Type 2 diabetes is a recognized independent cardio-vascular risk factor, which adds to other known risk factors. In in vitro or animal models, rosiglitazone and/or other thiazolidinediones induced favourable effects on the various mechanisms involved in atherosclerosis. In type 2 diabetic patients, rosiglitazone and/or other thiazolidinediones have shown beneficial effects on blood pressure, arterial wall, vasomotricity, PAI-1 levels and urinary albumin excretion. These data are briefly reviewed. They justify carrying out a large program of prospective studies aimed to assess the effects of rosiglitazone on cardiovascular morbidity and mortality in type 2 diabetic patients.
Valensi
P
P
Service d'Endocrinologie - Diabétologie - Nutrition, CHU Jean-Verdier, F - 93143 Bondy Cedex, France.
D000419:Albuminuria / Q000517:prevention & control; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D004730:Endothelium, Vascular / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D012307:Risk Factors; D000077154:Rosiglitazone; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones
D007004:Hypoglycemic Agents; D017395:Plasminogen Activator Inhibitor 1; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone